Vaccine efficacy is the percentage reduction in a disease in a group of people who received a vaccination in a clinical trial. It differs from vaccine effectiveness, which measures how well a vaccine works when given to people in the community outside of clinical trials.
All new
vaccines undergo clinical trials to test how well they work. The developers of
a vaccine candidate usually determine the main goals of their trial in their
clinical trial study protocol.
These goals are called the primary
endpoints. For many experimental COVID-19 vaccines currently in development,
the primary endpoints focus on preventing new cases of symptomatic COVID-19.
Scientists can calculate how well a
vaccine candidate works by looking at the difference in new cases of the
disease between the group receiving a placebo and the group receiving the
experimental vaccine.
This is called vaccine efficacy. For example, Pfizer/Biontech reported an efficacy of
95% for the COVID-19 vaccine. This means a 95% reduction in new cases of the
disease in the vaccine group compared with the placebo group.
Volunteers taking part in vaccine
clinical trials often undergo close monitoring. The trial team is usually aware
of the participants’ general health and any relevant health conditions.
Participants usually report any side
effects and may fill out daily symptom monitoring diaries.
Many clinical trials have exclusion
criteria such as pregnancy, particular health conditions, and age. Trials
involving experimental vaccines rarely include children or seniors until
scientists have collected a significant amount of safety data to protect these
groups from potential harm.
Vaccine efficacy only provides
information about how well a vaccine works under the conditions of the clinical
trial. Scientists usually base it on factors that they can quantify, such as
numbers of laboratory-confirmed cases of COVID-19.
But the ideal conditions of a
clinical trial do not necessarily reflect what is happening in the real world
outside of clinical trials.
Vaccine
effectiveness tells us how well a vaccine
works under real-world conditions once people outside of clinical trials
receive the vaccine.
Many factors can influence how a
vaccine performs outside of clinical trials. One of these is the health of
those receiving the vaccine. Underlying health conditions can affect vaccine
effectiveness.
Another factor is how the
disease-causing pathogen changes with time. The viruses that cause the flu are
prone to mutations that make vaccines less effective. Vaccine developers update
the flu shot every year to try to achieve a good match to the most prevailing
seasonal flu strains.
Source: Medical News Today
No comments:
Post a Comment